Medincell has partnered with AbbVie to develop and commercialize up to six innovative therapies using Medincell’s long-acting injectable platform. Medincell will conduct formulation and preclinical studies, including Chemistry, Manufacturing, and Controls (CMC) work, to advance a first candidate into clinical development. AbbVie will finance and lead clinical trials, regulatory approvals, manufacturing, and commercialization.
Medincell will receive an upfront payment of $35 million and is eligible for development and commercial milestones up to $1.9 billion and royalties on net sales.
Collaboration with Teva
Medincell’s UZEDY® is the first commercial product based on its BEPO® long-acting injection technology. Teva is responsible for developing and commercializing of UZEDY® and another long-acting olanzapine injection, mdc-TJK. Medincell may receive up to $222 million in milestones and royalties on sales of both products.
About BEPO® Technology
BEPO® precisely controls the delivery of drugs over extended periods from a small subcutaneous injection. It combines active ingredients with a bioresorbable deposit that releases the drug at a consistent therapeutic level, improving compliance, effectiveness, and accessibility.
About Medincell
Medincell is a biopharmaceutical company focused on developing long-acting injectable drugs. Its mission is to ensure patient compliance, enhance drug effectiveness, and reduce environmental impact through its proprietary BEPO® technology. Medincell’s first FDA-approved treatment based on BEPO®, UZEDY®, is marketed by Teva for the treatment of schizophrenia.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
